| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
7,710,000 |
| Market
Cap: |
3.08(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.352 - $3.11 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Trevena is a biopharmaceutical company. Co.'s primary product, OLINVYK™ (oliceridine) injection, is an opioid agonist for use in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. Co.'s product candidates include: TRV027, which is an angiotensin II type 1 receptor selective agonist, for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, which is a G-protein biased delta-opioid receptor agonist as a compound with a mechanism for the treatment of acute migraine; and TRV045, which is a S1P modulator.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
31,785 |
| Total Sell Value |
$0 |
$0 |
$0 |
$13,032 |
| Total People Sold |
0 |
0 |
0 |
1 |
| Total Sell Transactions |
0 |
0 |
0 |
1 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Gowen Maxine |
President & CEO |
• • – |
2016-10-17 |
4 |
GD |
$0.00 |
$0 |
D/D |
145,025 |
18,084 |
|
- |
|
| Gowen Maxine |
President & CEO |
• • – |
2016-09-29 |
4 |
GA |
$0.00 |
$0 |
I/I |
130,000 |
134,000 |
|
- |
|
| Gowen Maxine |
President & CEO |
• • – |
2016-09-29 |
4 |
GD |
$0.00 |
$0 |
D/D |
130,000 |
163,109 |
|
- |
|
| Gowen Maxine |
President & CEO |
• • – |
2016-05-27 |
4 |
B |
$7.08 |
$99,715 |
D/D |
14,084 |
293,109 |
2.81 |
- |
|
| Gowen Maxine |
President & CEO |
• • – |
2016-05-26 |
4 |
B |
$7.20 |
$28,800 |
I/I |
4,000 |
4,000 |
2.66 |
- |
|
| Gowen Maxine |
President & CEO |
• • – |
2016-05-26 |
4 |
B |
$7.19 |
$28,760 |
D/D |
4,000 |
279,025 |
2.81 |
- |
|
| Soergel David |
Sr. VP,Clinical Dev. & CMO |
• – – |
2015-12-10 |
4 |
AS |
$10.55 |
$287,139 |
D/D |
(27,217) |
1,750 |
|
- |
|
| Nunn Jason Raleigh |
Director |
– • – |
2015-12-09 |
4 |
A |
$0.00 |
$0 |
I/I |
4,271 |
4,271 |
|
- |
|
| Bourdow Carrie L. |
SVP, Chief Commercial OfficerO |
• – – |
2015-05-04 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
500 |
|
- |
|
| Gowen Maxine |
President & CEO |
• • – |
2015-02-20 |
4 |
GD |
$0.00 |
$0 |
D/D |
51,000 |
275,025 |
|
- |
|
| Limongelli John M |
Sr. VP,General Counsel & Secy |
• – – |
2014-12-12 |
4 |
B |
$4.14 |
$12,420 |
D/D |
3,000 |
12,000 |
2.74 |
- |
|
| Soergel David |
Sr. VP, Clinical Development |
• – – |
2014-12-10 |
4/A |
B |
$4.00 |
$5,000 |
D/D |
1,250 |
28,967 |
2.74 |
- |
|
| Moulder Leon O Jr |
Director |
– • – |
2014-12-10 |
4 |
B |
$4.06 |
$80,388 |
D/D |
19,800 |
50,000 |
2.39 |
- |
|
| Limongelli John M |
Sr. VP,General Counsel & Secy |
• – – |
2014-12-10 |
4 |
B |
$4.00 |
$36,000 |
D/D |
9,000 |
9,000 |
2.74 |
- |
|
| Cuca Roberto |
Sr. VP and CFO |
• – – |
2014-12-10 |
4 |
B |
$4.00 |
$100,000 |
D/D |
25,000 |
25,000 |
2.74 |
- |
|
| Yanni Barbara |
Director |
– • – |
2014-12-10 |
4 |
B |
$4.00 |
$5,000 |
D/D |
1,250 |
1,250 |
2.39 |
- |
|
| Dougherty Michael R |
Director |
– • – |
2014-12-10 |
4 |
B |
$4.00 |
$28,000 |
D/D |
7,000 |
7,000 |
2.39 |
- |
|
| Lark Michael W. |
Sr. VP, Research & CSO |
• – – |
2014-12-10 |
4 |
B |
$4.00 |
$20,000 |
D/D |
5,000 |
85,645 |
2.74 |
- |
|
| Soergel David |
Sr. VP, Clinical Development |
• – – |
2014-12-10 |
4 |
B |
$4.00 |
$5,000 |
D/D |
1,250 |
28,467 |
2.74 |
- |
|
| Gowen Maxine |
President & CEO |
• • – |
2014-12-10 |
4 |
B |
$4.00 |
$32,000 |
D/D |
8,000 |
326,025 |
2.81 |
- |
|
| Nohra Guy P |
10% Owner |
– – • |
2014-12-10 |
4 |
B |
$4.00 |
$2,000,000 |
I/I |
500,000 |
4,390,262 |
1.5 |
- |
|
| Sandell Scott D |
10% Owner |
– – • |
2014-12-10 |
4 |
B |
$4.00 |
$4,000,000 |
D/D |
1,000,000 |
4,811,691 |
2.45 |
- |
|
| Soergel David |
Sr. VP, Clinical Development |
• – – |
2014-12-09 |
4/A |
B |
$3.97 |
$1,985 |
D/D |
500 |
27,717 |
2.66 |
- |
|
| Moulder Leon O Jr |
Director |
– • – |
2014-12-09 |
4 |
B |
$3.96 |
$119,592 |
D/D |
30,200 |
30,200 |
2.39 |
- |
|
| Deegan Rosamond |
Sr VP, Bus Dev & Operations |
• – – |
2014-09-29 |
4 |
AS |
$7.00 |
$308 |
D/D |
(44) |
31,105 |
|
- |
|
142 Records found
|
|
Page 5 of 6 |
|
|
